Anatara Life sciences Ltd: Half-Year Financial Update December 2024.

Anatara Life sciences Ltd (ASX: ANR) reported a loss of AU$1,161,074 for the half-year ended December 31, 2024, compared to a loss of AU$679,189 in the prior corresponding period. Operating cash outflows increased to AU$899,504 from AU$289,043, with cash and cash equivalents at AU$1,051,721 as of December 31, 2024. The company remains a going concern, relying on potential capital raising, asset sales, or strategic disposals to sustain operations. Additionally, Anatara recognized AU$523,261 in R&D tax incentive income, significantly higher than the AU$254,825 recorded in December 2023. 

General and administrative expenses rose to AU$775,918 from AU$617,846, with notable increases in advertising, employee benefits, and share-based payment expenses. Research expenses surged to AU$912,890 from AU$337,794, reflecting heightened investment in project research. The company continues to adhere to AASB standards and has adopted all mandatory accounting updates while maintaining its commitment to financial compliance and strategic resource management.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com